Inactive Instrument

Press Releases Seagen Inc.

Equities

SGEN

US81181C1045

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	Mar. 28	AQ
Seagen Requests Director Review Of Unpatentability Decision In Adcetris® Patent PGR	Feb. 29	AQ
PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable	Jan. 30	AQ
Fitch Affirms Pfizer's Long-Term IDR at 'A'; Outlook Stable	Jan. 10	AQ
Seagen : Acquisition/Asset Disposal - Form 8-K	Dec. 14	PU
Seagen Inc. - ADCETRIS plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Dec. 11	AQ
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	Dec. 10	BU
Seagen Inc. - TUKYSA in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	Dec. 07	AQ
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	Dec. 06	BU
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Nov. 30	BU
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting	Nov. 03	BU
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate	Nov. 02	BU
Seattle Genetics: Q3 Earnings Snapshot	Nov. 01	AQ
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress	Nov. 01	BU
Antitrust & Competition Life Sciences Quarterly Update Q3 2023	23-10-25	AQ
Seagen Inc. - TIVDAK Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial	23-10-23	AQ
Astellas Pharma - Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV and KEYTRUDA in First-Line Advanced Bladder Cancer	23-10-23	AQ
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer	23-10-22	BU
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial	23-10-22	BU
Texas District Court Issues Amended Final Judgment in Patent Dispute between Daiichi Sankyo and Seagen	23-10-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Seagen Inc.

Equities

SGEN

US81181C1045

Press Releases

Filters